The company developing the drug, Excelis, now plans to focus it's attention on the ongoing kidney and liver cancer trials for the drug.
The Exelixis cancer drug cabozantinib failed to prolong survival in men with advanced prostate cancer, according to results from a phase III study announced Monday night.
The so-called COMET-1 study enrolled 960 men with advanced prostate cancer no longer responding to treatment with the chemotherapy drug docetaxel, Johnson & Johnson's Zytiga and/or Medivation's Xtandi. The patients were randomized to treatment with cabozantinib or the steroid prednisone and followed for survival. As reported Monday, cabozantinib reduced the risk of death by 10% compared to prednisone but the difference was not statistically significant. The study failed to achieve its primary endpoint.
Complete report: http://bit.ly/1ntFaCC
Source: The Street